S. Olafsson

TL;DR: The global estimate of viraemic HCV infections is lower than previous estimates, largely due to more recent prevalence estimates in Africa, and increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections.

TL;DR: The current treatment rate and efficacy are not sufficient to manage the disease burden of hepatitis C virus and alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver‐related deaths from increasing.

TL;DR: In this article , a literature review, Delphi process, and mathematical modelling were used to estimate hepatitis C virus (HCV) prevalence (viraemic infection, defined as HCV RNA-positive cases) and the cascade of care among people of all ages (age ≥ 0 years from birth) for the period between Jan 1, 2015 and Dec 31, 2030.

TL;DR: Findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.

TL;DR: A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies.